YBYanzhi Bi

Yanzhi Bi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yanzhi Bi has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effect of dosing interval on the pharmacokinetic interaction between montmorillonite powder and pyrotinib in rats

    by Xiaohuan Gao, Guangzhao He, Yanzhi Bi, Hui Luo, Jing Wu, Yuanyuan Zu, Yun Ji, Jingping Yu

    Aims: Montmorillonite powder (MP) can adsorb pyrotinib and reduce its bioavailability. This study investigated the effects of different dosing intervals on the pharmacokinetic interaction between MP and pyrotinib in rats. Methods: Eighteen male Sprague-Dawley rats were randomly assigned to three groups (n = 6/group): Control (pyrotinib alone), 0.5-h interval (MP given 0.5 h after pyrotinib), and 2.0-h interval (MP given 2.0 h after pyrotinib). Pyrotinib (10 mg/kg) was orally administered to all rats, followed by MP (240 mg/kg) or water (control) at designated time points. Blood samples were collected up to 24 h post-dose. Plasma pyrotinib concentrations were determined by a validated liquid chromatography-tandem mass spectrometry method. Pharmacokinetic parameters were calculated using WinNonlin. Results: The 0.5-h interval group showed substantially reduced pyrotinib exposure, with area under the curve (AUC) from time zero to last time point (AUC last ) and AUC from time zero to infinity (AUC inf ) decreasing by 31.2% and 31.3%, respectively, indicating statistically significant reductions (90% CIs C max reduction was 20.7%, which was not statistically significant (90% CI crossed 1.0). For the 2.0-h interval group, all GMRs were close to unity, but the wide 90% CIs (69.1%–137.6%) could not rule out a clinically meaningful impact. Conclusion: In rats, MP administration at an insufficient dosing interval markedly compromises pyrotinib systemic exposure, whereas adequate temporal separation largely mitigates this interaction. These findings underscore the urgent need for dedicated clinical pharmacokinetic studies to define the optimal dosing interval in humans and to minimize the risk of subtherapeutic pyrotinib exposure in clinical practice.

  • Open Access

    Immune‑related nephritis, ureteritis and cystitis secondary to immune checkpoint inhibitors: A case report and review of the literature

    by Guangquan Zhang, Silu Xu, Jing Wu, Qianqian Gao, Yanzhi Bi, Min Xiao

    Immune checkpoint inhibitors (ICIs) have beneficially impacted cancer therapy but are frequently associated with immune-related adverse events (irAEs), most commonly affecting the skin and gastrointestinal system. By contrast, genitourinary toxicities are rare and often underrecognized. The present case report outlines a 62-year-old male with metastatic colorectal cancer who developed pan-urinary tract irAEs (concurrent immune-related nephritis, ureteritis and cystitis) after exposure to three distinct classes of ICIs. The patient initially experienced pollakiuria, urinary urgency, dysuria and hematuria, which worsened after switching to cadonilimab and adebrelimab. This deterioration coincided with rising serum creatinine levels and lack of improvement with antibacterial treatment. Urinalysis revealed leukocyturia and hematuria, while imaging demonstrated bilateral hydroureteronephrosis and diffuse bladder wall thickening. A multidisciplinary evaluation led to the diagnosis of ICI-induced pan-urinary tract irAEs. Both urinary symptoms and renal function resolved rapidly after halting immunotherapy and starting glucocorticoid treatment, with no recurrence during follow-up. In addition, a comprehensive review of reported cases was conducted to characterize this rare irAE presentation and further propose both diagnostic criteria and management strategies to facilitate early detection and effective treatment.


  • Open Access

    Recombinant human adenovirus type 5 synergizes with anti-PD-L1 antibody to promote anti-hepatocellular carcinoma effects through multilevel remodeling of the immune microenvironment

    by Qiu Zhao, Min Xiao, Jian Ma, Xiaoqian Li, Cong Fu, Wenjing Ji, Lingna Ni, Jialin Fan, Qianqian Gao, Yanzhi Bi

    Background: Overcoming resistance to immune checkpoint inhibitors (ICIs) remains a critical challenge in the treatment for hepatocellular carcinoma (HCC). Methods: Our study evaluated the combined efficacy of the recombinant human adenovirus type 5 (H101) and an anti-PD-L1 antibody (APA) in C57BL/6N mouse model. Gene expression of STAT1 and CD274 (PD-L1) was analyzed by qPCR, and protein levels of PD-L1 and p-STAT1 were assessed via western blot and immunohistochemistry. IFN-γ secretion and immune cell infiltration were measured by ELISA and flow cytometry, respectively. Results: In vitro , H101 inhibited the proliferation and invasion and IFN-γ induced apoptosis in HCC cells, with IFN-γ upregulating the expression of STAT1 and CD274. Transfection with si-STAT1 significantly reduced the levels of both STAT1 and CD274/PD-L1. In vivo , the combination of H101 and APA demonstrated stronger anti-tumor activity, with upregulated IFN-γ expression and increased infiltration level of CD8+ T cell. Notably, si-STAT1 transfection reduced the expression of p-STAT1 and PD-L1, thereby diminishing the efficacy of both APA monotherapy and the H101+APA combination treatment. The combination therapy significantly reshaped the tumor microenvironment (TME) after si-STAT1 transfection. Conclusion: The combination of H101 and APA exhibited excellent anti-HCC efficacy, which may reshape the TME partially through the IFN-γ/STAT1/PD-L1 axis. These findings provide a promising strategy to overcome resistance to ICIs in HCC treatment.

  • Open Access

    Prognostic gene screening and experimental validation in renal clear cell carcinoma based on spatial transcriptomics and single-cell sequencing

    by Cong Fu, Lin Sun, Tong Zhou, Yanzhi Bi

    Background: Clear cell renal cell carcinoma (ccRCC) is characterized by high recurrence and metastatic potential, leading to poor clinical outcomes. There is a critical need to identify reliable prognostic biomarkers and therapeutic targets to improve patient stratification and personalized treatment. Methods: This study integrated single-cell RNA sequencing (scRNA-seq) data and spatial transcriptomics (ST) data to identify prognostic genes and therapeutic targets. Prognostic modeling and validation were performed using The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) datasets. In addition, functional analyses were conducted to explore the biological roles of candidate genes. Results: Seven prognostic genes (CYFIP2, MPPED2, HHLA2, ADAM8, ATP1A1, ARC, and MXD3) were identified and used to construct a risk model that stratified patients into high- and low-risk groups. The high-risk group exhibited significantly poorer survival, a finding validated in both TCGA and ICGC datasets. A nomogram incorporating risk score and age improved survival prediction accuracy, with Area Under the Curve (AUC) values of 0.79, 0.75, and 0.78 at 1, 3, and 5 years, respectively. ATP1A1 was highly expressed in endothelial cells and was significantly associated with M1 macrophages; thus, it was selected as a potential therapeutic target. Functional analyses revealed its role in angiogenesis inhibition and M1 macrophage polarization. Discussion: The risk model and nomogram demonstrate strong prognostic value and may aid in clinical risk stratification for ccRCC. ATP1A1 emerges as a potential therapeutic target, with functional implications in angiogenesis and immune modulation. These findings highlight the clinical relevance of the identified gene signatures and support the development of personalized treatment strategies for ccRCC patients.

  • Open Access

    Identification and validation of prognostic genes associated with mitochondrial nuclear genes in gastric cancer

    by Cong Fu, Lin Sun, Xiaoyue Zhou, Tong Zhou, Yanzhi Bi

    Mitochondrial-related nuclear genes (MNGs) have shown great importance in cancer diagnosis and prognosis, but their role in gastric cancer (GC) remains unclear. GC-related transcriptome data from the gene expression omnibus and cancer genome atlas databases were analyzed to identify differentially expressed MNGs. A prognostic risk model was constructed through univariate Cox and least absolute shrinkage and selection operator regression, validated by Kaplan–Meier (K–M) survival curve and receiver operating characteristic curve. This was followed by immune infiltration analysis, independent prognostic analysis, functional enrichment analysis, drug sensitivity analysis, drug prediction, molecular docking and construction of regulatory networks. Three prognostic genes (ATP8A2, COX15 and TARS2) were identified. The expression of TARS2 and COX15 was positively correlated with CNV, while ATP8A2 was unaffected. The risk model and nomogram, integrating risk score and clinicopathological factors, exhibited excellent predictive performance. A significant correlation was observed between prognostic genes and differential immune cells, such as T cells, B cells, and NK cells. BMS-754807, Gefitinib, JQ1, Lapatinib, and Sapitinib exhibited significant differences in sensitivity between the high-risk group and the low-risk group. The results of molecular docking showed TP8A2 has stable binding ability with cytosine, COX15 with indomethacin, and TARS2 with bisacodyl. RT-qPCR revealed downregulation of ATP8A2 and upregulation of COX15 and TARS2 in GC samples. MNGs, including ATP8A2, COX15, and TARS2, demonstrated significant associations with immune infiltration, CNV, and prognostic outcomes of GC.


  • Open Access

    Identification of key biomarkers and potential therapeutic drugs in nasopharyngeal carcinoma based on comprehensive bioinformatics analysis

    by Cong Fu, Lin Sun, Lili Zhang, Tong Zhou, Yanzhi Bi

    Nasopharyngeal carcinoma (NPC) is the most prevalent type of head- and -neck cancer, and its diagnosis and treatment are currently facing significant challenges. This study aimed to identify biomarkers associated with NPC by performing bioinformatic analysis on the GSE12452, GSE53819, and GSE64634 datasets from the GEO database. First, differentially expressed genes (DEGs) between NPC and normal nasopharyngeal tissues were screened. Then, these DEGs were subjected to RobustRank Aggregation analysis. Through Receiver Operating Characteristic (ROC) analysis and three machine-learning models, biomarkers such as DNAH5, ZMYND10, LRRC6, ARMC4, DNAI2, and DNALI1 were identified. Enrichment analysis was performed to uncover the common pathways of these biomarkers. Using the Comparative Toxicogenomics Database (CTD), target drugs for NPC were predicted based on these biomarkers. Additionally, immune infiltration analysis was carried out to study the relationship between these biomarkers and immune cells. A regulatory network was also constructed. It was found that these biomarkers are mainly involved in cytokine–cytokine receptor interaction, and some are part of common cancer-related signaling pathways. In addition, quantitative real time polymerase chain reaction (qRT-PCR) results showed that the expression levels of all biomarkers were significantly elevated in normal cell samples. DNAH5 and ZMYND10 were significantly higher in normal surrounding tissues. These findings provided potential support for the early clinical diagnosis and treatment of nasopharyngeal carcinoma patients.


  • Open Access

    Identification of Key Biomarkers and Potential Therapeutic Drugs in Nasopharyngeal Carcinoma Based on Comprehensive Bioinformatics Analysis

    by Cong Fu, Lili Zhang, Tong Zhou, Yanzhi Bi, Lin Sun

    Nasopharyngeal carcinoma (NPC) is the most prevalent type of head - and - neck cancer, and its diagnosis and treatment are currently facing significant challenges. This study aimed to identify biomarkers associated with NPC by performing bioinformatic analysis on the GSE12452, GSE53819, and GSE64634 datasets from the GEO database. First, differentially expressed genes (DEGs) between NPC and normal nasopharyngeal tissues were screened. Then, these DEGs were subjected to RobustRank Aggregation analysis. Through Receiver Operating Characteristic (ROC) analysis and three machine - learning models, biomarkers such as DNAH5, ZMYND10, LRRC6, ARMC4, DNAI2, and DNALI1 were identified. Enrichment analysis was performed to uncover the common pathways of these biomarkers. Using the Comparative Toxicogenomics Database (CTD), target drugs for NPC were predicted based on these biomarkers. Additionally, immune infiltration analysis was carried out to study the relationship between these biomarkers and immune cells. A regulatory network was also constructed. It was found that these biomarkers are mainly involved in cytokine - cytokine receptor interaction, and some are part of common cancer - related signaling pathways. In addition, quantitative real time polymerase chain reaction (qRT-PCR) results showed that the expression levels of all biomarkers were significantly elevated in normal cell samples. DNAH5 and ZMYND10 were significantly higher in normal surrounding tissues. These findings may offer valuable support for the early clinical diagnosis and treatment of NPC patients.

  • Open Access

    A prognostic model of lung adenocarcinoma constructed based on circadian rhythm genes and its potential clinical significance

    by Cong Fu, Lin Sun, Cuncheng Feng, Tong Zhou, Yanzhi Bi

    Background: Lung adenocarcinoma (LUAD) is a common pathological category of lung cancer. Circadian rhythm (CR) disruption has been demonstrated to impact on lung tumorigenesis in mouse models. The aim of this study was to mine genes relevant to CR in LUAD and construct a corresponding risk model.Methods: CRRGs from GSEA-MsigDB were filtered by overlapping DEGs in LUAD and NC specimens, two clusters with survival and clinical discrepancies, and CRRGs. Cox regression analysis (univariate and multivariate) was used to establish a CR-relevant risk model, which was validated in both the training and validation sets. Differences in immune infiltration, immunotherapy, and drug sensitivity between subgroups were explored. Prognostic gene expression was tested in clinical cancer and paracancer tissue samples using RT-qPCR.Results: A grand total of two prognostic genes (CDK1 and HLA-DMA) related to CR were screened. The AUC values of a CR-relevant risk model in predicting 1/3/5-years survival in LUAD patients were greater than 0.6, indicating that the efficiency of the model was decent. Then, the results of CIBERSORT demonstrated noticeable differences in the tumor microenvironment between CR-relevant high- and low-risk subgroups. In addition, the CR-relevant risk score could be performed to estimate the effectiveness of immunotherapy in LUAD patients. The sensitivity of three common drugs (homoharringtonine, lapatinib, and palbociclib) in LUAD could be evaluated by the CR-relevant risk model. Ultimately, the experimental results confirmed that the expression trends of CDK1 and HLA-DMA in our collected clinical samples were in line with the expression trends in the TCGA-LUAD dataset.Conclusion: In conclusion, a CR-relevant risk model based on CDK1 and HLA-DMA was constructed by using bioinformatics analysis, which might supply a new insight into the improved prognosis of LUAD.


  • Open Access

    Reverse resistance to immune checkpoint inhibitor in a patient with recurrent cardia cancer by intratumoral injection of recombinant human adenovirus type 5: a case report and literature review

    by Qiu Zhao, Min Xiao, Jian Ma, Cong Fu, Qianqian Gao, Yanzhi Bi

    Advanced metastatic cardia cancer is an intractable malignance with poor prognosis. It is often accompanied by upper digestive tract obstruction, which seriously affects the quality of patients. Therefore, effective relief of eating obstruction is an important goal in the treatment of cardia cancer. Immune checkpoint inhibitors (ICIs) have shown significant efficacy in cardia cancer, but only a small percentage of patients will benefit from them due to immune resistance. Oncolytic viruses have been shown to enhance the efficacy of ICIs by altering the immune microenvironment. This indicates that oncolytic virus has the potential value of overcoming the immune resistance of cardia cancer. Here, we present a case with local recurrent and multiple metastatic cardia cancer accompanied by eating obstruction. After 4 cycles of chemotherapy plus ICI therapy, the patient´s metastases were significant shrink, but the recurrent carida lesion were almost unchanged. Then we implemented exploratory local injection of recombinant human adenovirus type 5(H101) into recurrent cardia lesion by painless gastroscopy. Surprisingly, the cardia lesion shrank significantly, and the eating obstruction was greatly relieved. We also observed a significant increase of infiltrated CD4+T cells in biopsy tissues after H101 treatment. Our study not only conformed the value of oncolytic viruses to reverse ICI resistance in patients with gastric cancer, but also revealed its underlying impact on immune microenvironment.


  • Open Access

    Efficacy of Endoscopic Tissue Adhesive in Patients with Gastrointestinal Tumor Bleeding

    by Jun Shen, Lingna Ni, Changhong Zhu, Chunying Jiang, Wenyu Zhu, Yanzhi Bi

    Background Gastrointestinal tumors bleeding remains a significantly clinical challenge due to its resistance to conventional endoscopic hemostasis methods. While the efficacy of endoscopic tissue adhesives (ETA) in variceal bleeding has been established, its role in gastrointestinal tumor bleeding (GITB) remains ambiguous. Aims This study aims to assess the feasibility and effectiveness of ETA in the treatment of GITB. Methods The study enrolled 30 patients with GITB who underwent hemostasis through Histoacryl® tissue glue injection. Hemostasis success rates, ETA-related adverse events, and re-bleeding rates were evaluated. Results ETA application achieved successful hemostasis at all tumor bleeding sites, with immediate hemostasis observed in all 30 (100.0%) patients. Among the initially hemostasis cases, 5 patients (17.0%) experienced re-bleeding within 30 days, and the 60 day re-bleeding rate was 20.0% (6/30). Expect for one case of vascular embolism, no adverse events related with ETA application were reported. The 6 month survival was 93%. Conclusion ETA demonstrated excellent immediate hemostasis success rate in GITB cases and showed promising outcomes in prevention re-bleeding.